The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Where Summit Therapeutics ( SMMT -7.92%) falls on that spectrum is a big question mark right now. It has been among the hottest healthcare stocks to own over the past 12 months, as its valuation has ...

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...